Gyala Therapeutics — Series A (estimated) · €3M

Gyala Therapeutics, a spin-off of Hospital Clínic de Barcelona and IDIBAPS, raised €3M from Invivo Partners, Nara Capital and CDTI Innvierte with no single lead named. The funding launches a Phase I trial of GYA01, a first-in-class CD84-targeting CAR-T for acute myeloid leukaemia and T-ALL, at Hospital Clínic Barcelona and Hospital La Fe in Valencia.